2,144 Shares in Waters Corporation $WAT Acquired by Azzad Asset Management Inc. ADV

Azzad Asset Management Inc. ADV acquired a new stake in shares of Waters Corporation (NYSE:WAT) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 2,144 shares of the medical instruments supplier’s stock, valued at approximately $643,000.

Other hedge funds have also modified their holdings of the company. Integrated Wealth Concepts LLC increased its stake in Waters by 2.9% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock worth $386,000 after purchasing an additional 30 shares in the last quarter. Exchange Traded Concepts LLC increased its position in shares of Waters by 5.9% in the third quarter. Exchange Traded Concepts LLC now owns 630 shares of the medical instruments supplier’s stock worth $189,000 after acquiring an additional 35 shares in the last quarter. Penserra Capital Management LLC raised its holdings in shares of Waters by 13.1% during the second quarter. Penserra Capital Management LLC now owns 327 shares of the medical instruments supplier’s stock valued at $114,000 after acquiring an additional 38 shares during the period. Tokio Marine Asset Management Co. Ltd. lifted its position in shares of Waters by 1.8% in the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 2,264 shares of the medical instruments supplier’s stock valued at $679,000 after acquiring an additional 41 shares in the last quarter. Finally, CW Advisors LLC lifted its position in shares of Waters by 2.0% in the 2nd quarter. CW Advisors LLC now owns 2,112 shares of the medical instruments supplier’s stock valued at $737,000 after acquiring an additional 42 shares in the last quarter. 94.01% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. William Blair assumed coverage on Waters in a report on Monday, January 5th. They issued an “outperform” rating for the company. Guggenheim began coverage on Waters in a research report on Tuesday, January 6th. They set a “buy” rating and a $440.00 price objective for the company. Wall Street Zen downgraded Waters from a “buy” rating to a “hold” rating in a report on Sunday. TD Cowen reissued a “hold” rating on shares of Waters in a research report on Wednesday, November 5th. Finally, Morgan Stanley began coverage on shares of Waters in a report on Monday, December 1st. They set an “equal weight” rating and a $423.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, Waters has a consensus rating of “Moderate Buy” and a consensus target price of $399.12.

Key Headlines Impacting Waters

Here are the key news stories impacting Waters this week:

• Positive Sentiment: Q4 results slightly beat expectations — Waters reported non-GAAP EPS of $4.53 (vs. $4.50 consensus) and revenue of ~$932M, with revenue up ~6.9% YoY and strong chemistry and LC‑MS demand. This underpins near-term profitability and recurring revenue trends. Press Release: Q4 and FY 2025 Results
• Positive Sentiment: BD combination closed — Waters completed the Reverse Morris Trust transaction with BD, creating a larger life‑sciences player and giving Waters access to BD’s biosciences & diagnostic portfolio and scale benefits that management expects to convert into margin expansion over time. This materially changes the company’s revenue base and strategic runway. PR Newswire: BD Combination
• Neutral Sentiment: Ambitious FY 2026 targets tied to integration — Management set FY 2026 EPS guidance of $14.30–$14.50 and projected revenue roughly $6.4B–$6.46B, with a targeted ~28.1% margin as BD assets are integrated. The FY EPS range slightly exceeds consensus but reflects the enlarged company post-transaction; realization depends on execution. MSN: FY 2026 Projections
• Negative Sentiment: Q1 2026 EPS guidance misses Street — Waters guided Q1 EPS to $2.25–$2.35 versus a ~$2.52 consensus, prompting a sell‑side reaction and an intra‑day share drop as investors priced in near‑term softness from the transition and integration-related dynamics. Yahoo Finance: Q1 Forecast Below Estimates
• Negative Sentiment: Analyst reaction and rating change — Some analysts have trimmed near‑term ratings or moved to a hold stance reflecting uncertainty around integration execution, near‑term EPS cadence, and the enlarged company’s valuation multiple. This adds selling pressure while investors reassess the combined company story. Article: Rating Lowered to Hold

Waters Trading Down 14.1%

Shares of NYSE:WAT opened at $327.52 on Tuesday. The company has a current ratio of 1.53, a quick ratio of 1.08 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $19.50 billion, a PE ratio of 30.10, a P/E/G ratio of 3.19 and a beta of 1.18. Waters Corporation has a 1 year low of $275.05 and a 1 year high of $414.15. The firm has a fifty day moving average price of $386.44 and a 200 day moving average price of $347.52.

Waters (NYSE:WAT) last announced its quarterly earnings results on Thursday, February 12th. The medical instruments supplier reported $4.53 earnings per share for the quarter, topping analysts’ consensus estimates of $4.50 by $0.03. Waters had a return on equity of 36.59% and a net margin of 20.89%.The company had revenue of $932.36 million during the quarter, compared to analysts’ expectations of $928.17 million. During the same quarter in the previous year, the firm earned $4.10 earnings per share. The business’s quarterly revenue was up 6.9% compared to the same quarter last year. Analysts expect that Waters Corporation will post 12.86 EPS for the current fiscal year.

About Waters

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.